title: Argatroban inhibits intraocular fibrin formation after vitrectomy in rabbits.
abstract: OBJECTIVE
  To examine whether the specific thrombin inhibitor argatroban can prevent anterior chamber, pupillary area, and anterior vitreous fibrin formation after vitrectomy and lensectomy in rabbits.
  
  
  METHODS
  Argatroban was infused into the vitreous cavities of Japanese albino rabbits for 5 minutes after pars plana vitrectomy and lensectomy. Slitlamp microscopy and indirect ophthalmoscopy were performed at postoperative hours 0.5, 1, 2, 3, and 6, and at postoperative days 1, 2, 3, and 7, and the amounts of fibrin formation in the anterior chamber, pupillary area, and anterior vitreous were scored from grade 0 to 4.
  
  
  RESULTS
  Argatroban prevented fibrin formation from 0.5 hours postoperatively in a dose-dependent manner. In the eyes treated with 0.01% argatroban, the median score for postoperative fibrin formation was significantly less than that in control eyes between hours 1 and 3 (hour 1, P =.02; hour 2, P =.005; and hour 3, P =.003); the eyes treated with 0.003% argatroban also had significantly less fibrin than control eyes between 1 and 2 hours (hour 1, P =.005; hour 2, P =.03).
  
  
  CONCLUSIONS
  These results indicate that argatroban inhibits intraocular fibrin formation in an experimental rabbit model.
  
  
  CONCLUSIONS
  Argatroban may be useful clinically in cases that often produce fibrin postoperatively, such as proliferative vitreoretinopathy and proliferative diabetic retinopathy.
authors.affiliation: 1-1-39 Sakaigawa, Nishi-ku, Osaka 550-0024, Japan. tanemem@osk2.3web.ne.jp
authors.forename: T
authors.initials: T
authors.lastname: Maeno
authors.forename: Y
authors.initials: Y
authors.lastname: Tano
authors.forename: T
authors.initials: T
authors.lastname: Mano
authors.forename: H
authors.initials: H
authors.lastname: Takenaka
mesh_terms: D000818:Animals; D000867:Anterior Chamber / Q000187:drug effects / Q000378:metabolism; D000991:Antithrombins / Q000008:administration & dosage / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D005337:Fibrin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007908:Lens, Crystalline / Q000601:surgery; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000627:therapeutic use; D010875:Pipecolic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy*; D011817:Rabbits; D013449:Sulfonamides; D013997:Time Factors; D014821:Vitrectomy; D014822:Vitreous Body / Q000187:drug effects / Q000378:metabolism
chemical_list: D000991:Antithrombins; D009883:Ophthalmic Solutions; D010875:Pipecolic Acids; D013449:Sulfonamides; D005337:Fibrin; D001120:Arginine; C031942:argatroban